Pakistan to begin local vaccine production from May

[Imran Khan]

Pakistan to begin local vaccine production from May

A health worker administers a dose of Chinese-made Sinopharm vaccine to a senior citizen during the coronavirus vaccination campaign at a private hospital in Karachi on Thursday, April 08, 2021. — PPI/File
The National Institute of Health's officials said Wednesday Pakistan would start the local production of CanSinoBio's coronavirus vaccine next month.
The NIH officials said the arrangements to prepare CanSinoBio's coronavirus vaccine have been done, while the raw material for the vaccine would reach Pakistan in early May.
Chinese experts are also present in Islamabad to help in the preparation of the vaccine, officials said, adding NIH had started the venture in collaboration with a Chinese company.
The official said they were hopeful that the single-dose vaccine would be available by the end of May for public inoculation.
It is pertinent to mention here that CanSinoBio's officials had trained NIH experts to prepare vaccine doses.

Pakistan to begin local vaccine production from May

The National Institute of Health's officials said Wednesday Pakistan would start the local production of CanSinoBio's coronavirus vaccine next month. The NIH officials said the arrangements to...

www.thenews.com.pk

 

[Ahmad Bhutta]

A single dose vaccine despite having less efficacy compared to double dose is more effective in curbing the spread of corona , one because double dose takes long time to develop immunity by then many people catch the virus
2nd it will save lives it starts working after a single dose

 

[Clutch]

Pakistan to begin local vaccine production from May

A health worker administers a dose of Chinese-made Sinopharm vaccine to a senior citizen during the coronavirus vaccination campaign at a private hospital in Karachi on Thursday, April 08, 2021. — PPI/File
The National Institute of Health's officials said Wednesday Pakistan would start the local production of CanSinoBio's coronavirus vaccine next month.
The NIH officials said the arrangements to prepare CanSinoBio's coronavirus vaccine have been done, while the raw material for the vaccine would reach Pakistan in early May.
Chinese experts are also present in Islamabad to help in the preparation of the vaccine, officials said, adding NIH had started the venture in collaboration with a Chinese company.
The official said they were hopeful that the single-dose vaccine would be available by the end of May for public inoculation.
It is pertinent to mention here that CanSinoBio's officials had trained NIH experts to prepare vaccine doses.

Pakistan to begin local vaccine production from May

The National Institute of Health's officials said Wednesday Pakistan would start the local production of CanSinoBio's coronavirus vaccine next month. The NIH officials said the arrangements to...

www.thenews.com.pk

That is great news. What is the production capacity of this facility?

 

[Imran Khan]

 

[UKBengali]

If it is Sinopharm then single dose strategy is a bad idea as Chilean study shows one dose is only 3% effective, compared to around 55% for 2 doses.

 

[Imran Khan]

If it is Sinopharm then single dose strategy is a bad idea as Chilean study shows one dose is only 3% effective, compared to around 55% for 2 doses.

i think pakistan have better study then chile

 

[truthfollower]

CanSinoBio's coronavirus vaccine? is it good vaccine? whats the name of vaccine

 

[Sulman Badshah]

If it is Sinopharm then single dose strategy is a bad idea as Chilean study shows one dose is only 3% effective, compared to around 55% for 2 doses.

UAE and german sinopharm study show efficacy with 2 doses upto 85-90%


But I think single dose of 65-75 % eficacy cansinobio strategy is better

 

[N.Siddiqui]

[

i think pakistan have better study then chile

There is another initiative with Searle Pakistan, and another China firm.

Searle, Chinese firm strike deal to make Covid vaccine in Pakistan

Communique says that the vaccine is in the final stages of its trial and has shown promising results.

www.dawn.com

 

[masterchief_mirza]

If it is Sinopharm then single dose strategy is a bad idea as Chilean study shows one dose is only 3% effective, compared to around 55% for 2 doses.

Not sure where you got those figures..

Lancet:



"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

• Feng-Cai Zhu, MSc †
• Prof Xu-Hua Guan, PhD †
• Prof Yu-Hua Li, PhD
• Prof Jian-Ying Huang, MD
• Prof Tao Jiang, PhD
• Prof Li-Hua Hou, PhD
• et al.
• Show all authors
• Show footnotes

Published:July 20, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31605-6


PlumX Metrics


Summary
Background
This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study.
Methods
This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 × 1011 viral particles per mL or 5 × 1010viral particles per mL, or placebo. Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm. The randomisation list (block size 4) was generated by an independent statistician. Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation. The primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28. The primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days. All recruited participants who received at least one dose were included in the primary and safety analyses. This study is registered withClinicalTrials.gov, NCT04341389.
Findings
603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020. 508 eligible participants (50% male; mean age 39·7 years, SD 12·5) consented to participate in the trial and were randomly assigned to receive the vaccine (1 × 1011 viral particles n=253; 5 × 1010 viral particles n=129) or placebo (n=126). In the 1 × 1011 and 5 × 1010 viral particles dose groups, the RBD-specific ELISA antibodies peaked at 656·5 (95% CI 575·2–749·2) and 571·0 (467·6–697·3), with seroconversion rates at 96% (95% CI 93–98) and 97% (92–99), respectively, at day 28. Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19·5 (95% CI 16·8–22·7) and 18·3 (14·4–23·3) in participants receiving 1 × 1011 and 5 × 1010 viral particles, respectively. Specific interferon γ enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85–93) of 253 and 113 (88%, 81–92) of 129 participants in the 1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Solicited adverse reactions were reported by 183 (72%) of 253 and 96 (74%) of 129 participants in the 1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Severe adverse reactions were reported by 24 (9%) participants in the 1 × 1011 viral particles dose group and one (1%) participant in the 5 × 1010 viral particles dose group. No serious adverse reactions were documented."

 

[VCheng]

There is another initiative with Searle Pakistan, and another China firm.

Is this actual manufacture, or simply repacking of bulk vaccine into individual doses?

Pakistan to import Chinese Cansino COVID vaccine in bulk to package 3 million doses locally: minister

Pakistan will import Chinese Cansino Biologics COVID-19 vaccines in bulk to package 3 million doses locally, said the minister in charge for COVID operations.

www.reuters.com

 

[masterchief_mirza]

Secondly, there is an excellent reason for a single dose strategy in Pakistan - patients are less likely to turn up on time for a second dose for a variety of reasons in Pakistan. This is a well known phenomenon.

 

[truthfollower]

@Imran Khan iski koi video hi nae youtube per kis qisam ki vaccine hamaaray hisaay aai gi

 

[UKBengali]

Not sure where you got those figures..

Lancet:



"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

• Feng-Cai Zhu, MSc †
• Prof Xu-Hua Guan, PhD †
• Prof Yu-Hua Li, PhD
• Prof Jian-Ying Huang, MD
• Prof Tao Jiang, PhD
• Prof Li-Hua Hou, PhD
• et al.
• Show all authors
• 
  
• Show footnotes

Published:July 20, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31605-6

PlumX Metrics


Summary
Background
This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study.
Methods
This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 × 1011 viral particles per mL or 5 × 1010viral particles per mL, or placebo. Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm. The randomisation list (block size 4) was generated by an independent statistician. Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation. The primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28. The primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days. All recruited participants who received at least one dose were included in the primary and safety analyses. This study is registered withClinicalTrials.gov, NCT04341389.
Findings
603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020. 508 eligible participants (50% male; mean age 39·7 years, SD 12·5) consented to participate in the trial and were randomly assigned to receive the vaccine (1 × 1011 viral particles n=253; 5 × 1010 viral particles n=129) or placebo (n=126). In the 1 × 1011 and 5 × 1010 viral particles dose groups, the RBD-specific ELISA antibodies peaked at 656·5 (95% CI 575·2–749·2) and 571·0 (467·6–697·3), with seroconversion rates at 96% (95% CI 93–98) and 97% (92–99), respectively, at day 28. Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19·5 (95% CI 16·8–22·7) and 18·3 (14·4–23·3) in participants receiving 1 × 1011 and 5 × 1010 viral particles, respectively. Specific interferon γ enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85–93) of 253 and 113 (88%, 81–92) of 129 participants in the 1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Solicited adverse reactions were reported by 183 (72%) of 253 and 96 (74%) of 129 participants in the 1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Severe adverse reactions were reported by 24 (9%) participants in the 1 × 1011 viral particles dose group and one (1%) participant in the 5 × 1010 viral particles dose group. No serious adverse reactions were documented."

Like I said real-world Chilean data where they jabbed millions of people with 90:10 Sinopharmfizer vaccine ratio.

One dose is practically pointless as the Chileans said it provided 3% protection from symptomatic infection.

 

[Imran Khan]

CanSinoBio's coronavirus vaccine? is it good vaccine? whats the name of vaccine

@Imran Khan iski koi video hi nae youtube per kis qisam ki vaccine hamaaray hisaay aai gi

its just nice vaccine local one . we have trust in local products mam. i drink local alcohol 20 years kuch hoa mujhy ?